BioXcel Therapeutics, Inc. (BTAI) Stock Forecast
BTAI analyst forecast
as of September 13, 2026- Analyst consensus
- Buy 3.67 / 5 from 3 analysts
- Price target
- $21.50 average of analyst targets
- Upside to target
- +44,785.2% from the latest close
- Next earnings
- —
- 52-week range
- $0.04 – $2.33
BTAI analyst ratings
3 analystsNumber of analysts at each rating.
BTAI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BTAI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.01 | −$1.01 | −$1.01 | −$2.16 | +53.3% | 1 |
| Current fiscal year (2026) | −$2.70 | −$2.70 | −$2.70 | −$5.71 | +52.7% | 1 |
| Next fiscal year (2027) | −$2.14 | −$2.14 | −$2.14 | −$2.70 | +20.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BTAI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $191,390 | $191,390 | $191,390 | +95.3% | 1 |
| Current fiscal year (2026) | $769,920 | $769,920 | $769,920 | +19.9% | 1 |
| Next fiscal year (2027) | $20.8M | $20.8M | $20.8M | +2,598.4% | 1 |
BTAI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BTAI revenue: reported and forecast
BTAI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.97 | −$0.97 | −$0.97 | −$1.01 | −$1.01 | +4.1% | 0 up · 1 down |
| Current fiscal year (2026) | −$2.62 | −$2.62 | −$2.62 | −$2.70 | −$2.70 | +3.1% | 0 up · 1 down |
| Next fiscal year (2027) | −$1.54 | −$1.54 | −$1.54 | −$2.14 | −$2.14 | +39.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BTAI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BTAI beat in 6 of 12.
What analysts expect from BTAI
3 analysts cover BioXcel Therapeutics; their consensus rating is buy (3.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.50, 44,785.2% above the latest close of $0.05. Analysts expect earnings of −$2.70 per share for 2026, +52.7% from a year earlier. For 2027 the average estimate is −$2.14 per share on revenue of $20.8 million. BioXcel Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: BTAI income statement, BTAI key metrics, BTAI chart. See the BTAI stock overview for the latest quote and news.
BTAI forecast FAQ
What is BioXcel Therapeutics's price target?
The average analyst price target for BioXcel Therapeutics is $21.50, 44,785.2% above the latest close of $0.05.
Is BioXcel Therapeutics a buy, hold or sell?
Of 3 analysts covering BioXcel Therapeutics, 1 rate it a strong buy, 1 a buy, 0 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BioXcel Therapeutics's EPS forecast?
Analysts forecast −$2.70 per share for 2026 (range −$2.70 to −$2.70); for 2027 the estimate is −$2.14.
What is BioXcel Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.8 million, growth of 19.9%; for 2027 it is $20.8 million.
Does BioXcel Therapeutics usually beat earnings estimates?
BioXcel Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.